Thursday, August 9, 2018

Ligand Offers To Buy Vernalis For $43M

San Diego-based Ligand Pharmaceuticals said today that it has made an offer to buy UK-based Vernalis pcl, in a deal worth $43M in cash. According to Ligand, the deal requires approval by Vernalis shareholders. Vernalis a biotechnology company working on structure-based drug discovery. Vernalis is being advised by Evercore in a formal sales process.